Seeking Alpha

More on Alexion Pharmaceuticals' (ALXN) Q3 report: Steers revenue guidance higher, now seeing...

More on Alexion Pharmaceuticals' (ALXN) Q3 report: Steers revenue guidance higher, now seeing $770M-$775M from the previously announced range of $760M-$768M. Lowers the expectation for its GAAP tax rate for FY11 to a range of 20%-22%, from 30%-32%. Shares +1% premarket. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs